Psychotic symptoms associated with switching from oros methylphenidate to modified-release methylphenidate Oros metilfenidattan modifiye-salınımlı metilfenidata geçişte psikotik belirtiler
Anadolu Psikiyatri Dergisi, cilt.18, sa.4, ss.410-412, 2017 (SCI-Expanded, Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 18 Sayı: 4
- Basım Tarihi: 2017
- Doi Numarası: 10.5455/apd.227212
- Dergi Adı: Anadolu Psikiyatri Dergisi
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.410-412
- Anahtar Kelimeler: Child, Methylphenidate, Psychosis, Switching
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Methylphenidate (MPH), the firstline medication treatment of attention deficit hyperactivity disorder (ADHD), may be associated with behavioral adverse effects. Amongst these reactions, psychotic symptoms are the most challenging ones for clinicans. For ADHD patients with suboptimal symptom control, switching MPH formulations may be helpful. The possible differences in the risk of adverse effects between long acting MPH formulations is largely unknown. Hereby, we report a child case who developed psychotic symptoms when switching from osmotic release oral system (OROS) MPH to modified-release MPH.